Open AccessWhat Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery In Vivo?
Author(s) -
Michael Hadjiargyrou
Publication year - 2021
Publication title -
nucleic acid therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.255
H-Index - 67
eISSN - 2159-3345
pISSN - 2159-3337
DOI - 10.1089/nat.2021.0013
Subject(s) - nucleic acid , covid-19 , gene delivery , coronavirus , genetic enhancement , dna vaccination , dna , rna , immune system , virology , computational biology , biology , medicine , disease , immunology , gene , genetics , infectious disease (medical specialty) , immunization , pathology
The utilization of the m RNA-based Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines represents the culmination of many years of nonviral nucleic acid delivery, but more importantly, they signify a massive clinical scientific success . Scientists working in the area of nucleic acid delivery using lipid nanoparticles will undoubtedly be energized by the success of these vaccines and begin to collect much needed data in the realm of nonviral-based RNA and DNA delivery, specifically, the use of lipid nanoparticles, the immune response, safety, and efficacy. It is easily conceivable that in the future we can utilize these data to help streamline our approach for the delivery of DNA for gene therapy and regulatory RNAs for therapeutic and regenerative medicine (ie, wound repair) applications .